4.7 Article

Development of New Meridianin/Leucettine-Derived Hybrid Small Molecules as Nanomolar Multi-Kinase Inhibitors with Antitumor Activity

期刊

BIOMEDICINES
卷 9, 期 9, 页码 -

出版社

MDPI
DOI: 10.3390/biomedicines9091131

关键词

meridianins; leucettine; marine-inspired kinase inhibitors; DAPK1; FMS; LCK; LYN; molecular modeling; ADME studies

资金

  1. KIST Institutional programs from the Korea Institute of Science and Technology [2E31140]
  2. Creative Fusion Research Program through the Creative Allied Project - National Research Council of Science Technology [CAP-12-1KIST]
  3. National Research Foundation of Korea (NRF) - Korean government (MSIT) [NRF-2018R1A5A2023127]
  4. National Research Foundation of Korea [2E31140] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

A new series of hybrid small molecules based on marine natural products were designed and synthesized, with compound 5g identified as the most potent multiple kinase inhibitor. It showed significant antiproliferative activity against various cancer cell lines, making it a potential lead compound for novel marine-derived kinase modulators.
Although the sea ecosystem offers a broad range of bioactivities including anticancer, none of the FDA-approved antiproliferative protein kinase inhibitors are derived from a marine source. In a step to develop new marine-inspired potent kinase inhibitors with antiproliferative activities, a new series of hybrid small molecules (5a-5g) was designed and synthesized based on chemical moieties derived from two marine natural products (Meridianin E and Leucettamine B). Over a panel of 14 cancer-related kinases, a single dose of 10 mu M of the parent hybrid 5a possessing the benzo[d][1,3]dioxole moiety of Leucettamine B was able to inhibit the activity of FMS, LCK, LYN, and DAPK1 kinases with 82.5 +/- 0.6, 81.4 +/- 0.6, 75.2 +/- 0.0, and 55 +/- 1.1%, respectively. Further optimization revealed the most potent multiple kinase inhibitor of this new series (5g) with IC50 values of 110, 87.7, and 169 nM against FMS, LCK, and LYN kinases, respectively. Compared to imatinib (FDA-approved multiple kinase inhibitor), compound 5g was found to be similar to 9- and 2-fold more potent than imatinib over both FMS and LCK kinases, respectively. In silico docking simulation models of the synthesized compounds within the active site of FMS, LCK, LYN, and DAPK1 kinases offered reasonable explanations of the elicited biological activities. In an in vitro anticancer assay using a library of 60 cancer cell lines that include blood, lung, colon, CNS, skin, ovarian, renal, prostate, and breast cancers, it was found that compound 5g was able to suppress 60 and 70% of tumor growth in leukemia SR and renal RXF 393 cell lines, respectively. Moreover, an ADME study indicated a suitable profile of compound 5g concerning cell permeability and blood-brain barrier (BBB) impermeability, avoiding possible CNS side effects. Accordingly, compound 5g is reported as a potential lead towards novel antiproliferative marine-derived kinase modulators.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据